Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iloprost for bone healing in proximal humeral fracture
NCT04543682Phase 2Unknown
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2022
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iloprost in proximal humerus fracture (PHF) (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Toxicity grading in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) at 52 weeks and Tip Apex Distance at 12 weeks. Status: unknown.
02
Drugs
iloprost
03
Conditions
proximal humerus fracture (PHF)
Beyond the preview
Go deeper on NCT04543682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543682.